Does injectable TRT actually raise blood pressure? Let's check the evidence

What did @drjorgeyamamoto actually say?

Here is the problem: the transcript provided does not match the caption. The caption describes a substantive clinical claim, that injectable testosterone replacement therapy can raise blood pressure through direct cardiovascular effects and through aromatization into estradiol. The actual transcript is incoherent, likely a transcription error or auto-caption failure. There are no real statements to quote directly from the spoken content.

So this fact-check will focus on the claim as stated in the caption, because that is the only verifiable medical content available. The caption claims that injectable TRT can raise blood pressure in some individuals, both from testosterone's direct cardiovascular effect and from excess estradiol produced via aromatization. That is a specific, testable claim, and it deserves a serious look.

Does the science back this up?

Partially, yes. But the picture is more complicated than the caption suggests, and the framing matters a lot.

On blood pressure specifically, the evidence is genuinely mixed. A 2018 meta-analysis by Corona et al. in the Journal of Sexual Medicine found no significant increase in systolic or diastolic blood pressure in men on TRT compared to placebo across randomized controlled trials. However, observational data tells a different story. The TRAVERSE trial (Lincoff et al., 2023, New England Journal of Medicine) found that testosterone therapy in middle-aged men with hypogonadism and elevated cardiovascular risk did not increase major adverse cardiac events, but the study was not powered specifically for blood pressure as a primary endpoint.

Where the caption gets more traction is in the hematocrit and polycythemia pathway. TRT reliably increases red blood cell mass, which does increase blood viscosity and can secondarily raise blood pressure. That mechanism is real and documented. The estradiol aromatization angle is more speculative as a primary driver of hypertension specifically, even if excess estradiol has other cardiovascular implications.

What did they get wrong (or right)?

The caption gets the aromatization mechanism broadly right, testosterone does convert to estradiol via aromatase, and elevated estradiol is a real side effect profile item in TRT patients. But framing estradiol excess as a driver of blood pressure elevation is where the evidence gets thin. Most research linking estradiol to cardiovascular outcomes focuses on atherosclerotic risk markers and endothelial function, not acute blood pressure changes.

What the caption does not mention is arguably more important: the hematocrit effect. Erythrocytosis is the most consistently documented cardiovascular risk from injectable testosterone, particularly with longer-acting esters like cypionate and enanthate. Bachman et al. (2010, Journal of Clinical Endocrinology and Metabolism) showed dose-dependent increases in hemoglobin and hematocrit with testosterone administration. That mechanism, thicker blood raising vascular resistance, is a more defensible explanation for blood pressure changes than aromatization.

Credit where it is due: the qualifier "in certain individuals" is accurate. Not everyone on TRT experiences hypertension. Risk is higher in older men, those with pre-existing hypertension, or those on supraphysiologic doses.

What should you actually know?

If you are on injectable TRT and your blood pressure is creeping up, there are a few things worth discussing with your prescribing clinician.

• Get your hematocrit checked. Erythrocytosis is the most evidence-supported cardiovascular risk from injectable testosterone and is easily monitored with routine blood work.
• Estradiol monitoring matters, but not primarily for blood pressure. Excess estradiol causes gynecomastia, mood changes, and libido issues. Its role in hypertension is not well established as a standalone mechanism.
• Injection frequency can affect peak hormone levels. Twice-weekly injections of cypionate or enanthate tend to produce more stable serum testosterone and estradiol levels than once-weekly dosing, which may reduce side effect burden. This is a conversation for your provider, not a self-adjustment situation.
• The TRAVERSE trial (2023) is the largest cardiovascular safety RCT for TRT to date. It is reassuring at a population level, but it enrolled men with specific cardiovascular risk profiles, so generalizing to all TRT users has limits.

Bottom line: the claim in the caption is not wrong, but it is incomplete and slightly misattributes the mechanism. The hematocrit pathway deserves at least equal billing with the estradiol story.